Abstract:Background: Rapid-acting antidepressants (RAADs), including dissociative anesthetics, psychedelics, and empathogens, elicit rapid and sustained therapeutic improvements in psychiatric disorders by purportedly modulating neuroplasticity, neurotransmission, and immunity. These outcomes may be mediated by, or result in, an acute and/or sustained entrainment of epigenetic processes, which remodel chromatin structure and alter DNA accessibility to regulate gene expression. Methods: In this perspective, we present an overview of the known mechanisms, knowledge gaps, and future directions surrounding the epigenetic effects of RAADs, with a focus on the regulation of stress-responsive DNA and brain regions, and on the comparison with conventional antidepressants. Main body: Preliminary correlative evidence indicates that administration of RAADs is accompanied by epigenetic effects which are similar to those elicited by conventional antidepressants. These include changes in DNA methylation, post-translational modifications of histones, and differential regulation of non-coding RNAs in stress-responsive chromatin areas involved in neurotrophism, neurotransmission, and immunomodulation, in stress-responsive brain regions. Whether these epigenetic changes causally contribute to the therapeutic effects of RAADs, are a consequence thereof, or are unrelated, remains unknown. Moreover, the potential cell type-specificity and mechanisms involved are yet to be fully elucidated. Candidate mechanisms include neuronal activity- and serotonin and Tropomyosine Receptor Kinase B (TRKB) signaling-mediated epigenetic changes, and direct interaction with DNA, histones, or chromatin remodeling complexes. Conclusion: Correlative evidence suggests that epigenetic changes induced by RAADs accompany therapeutic and side effects, although causation, mechanisms, and cell type-specificity remain largely unknown. Addressing these research gaps may lead to the development of novel neuroepigenetics-based precision therapeutics.

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants

Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections

Synaptic plasticity in depression: molecular, cellular and functional correlates

A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists

Structural neural plasticity evoked by rapid-acting antidepressant interventions

Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments

Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model

Role of BDNF in the pathophysiology and treatment of depression: Activity‐dependent effects distinguish rapid‐acting antidepressants

Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions

Phytochemicals That Act on Synaptic Plasticity as Potential Prophylaxis against Stress-Induced Depressive Disorder

Frontal lobe synaptic plasticity in development and disease: modulation by the dopamine D1 receptor

Epigenetic mechanisms of rapid-acting antidepressants

Synaptic basis of rapid antidepressant action

Neurobiology of the Rapid-Acting Antidepressant Effects of Ketamine: Impact and Opportunities

Occlusion of dopamine-dependent synaptic plasticity in the prefrontal cortex mediates the expression of depressive-like behavior and is modulated by ketamine

Stress, mental disorder and ketamine as a novel, rapid acting treatment

Distinct synaptic mechanisms drive the behavioral response to acute stress and rapid correction by ketamine

signaling mediates fast antidepressant action

Stress during the COVID-19 pandemic - impact on neuroplasticity

Studying synaptic plasticity in the human brain and opportunities for drug discovery

Epigenetic modulation of inflammation and synaptic plasticity promotes resilience against stress in mice